Detalhe da pesquisa
1.
Adherence in HCV Treatment: What We Know.
Semin Liver Dis
; 2024 Apr 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-38657680
2.
Safety, Pharmacokinetics, and Efficacy Signals of Larsucosterol (DUR-928) in Alcohol-Associated Hepatitis.
Am J Gastroenterol
; 119(1): 107-115, 2024 Jan 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37011138
3.
AGA Clinical Practice Update on the Evaluation and Management of Acute Kidney Injury in Patients With Cirrhosis: Expert Review.
Clin Gastroenterol Hepatol
; 20(12): 2707-2716, 2022 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-36075500
4.
Liver Transplantation Following Yttrium-90 Radioembolization: 15-Year Experience in 207-Patient Cohort.
Hepatology
; 73(3): 998-1010, 2021 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-32416631
5.
Glecaprevir-Pibrentasvir for 8 or 12 Weeks in HCV Genotype 1 or 3 Infection.
N Engl J Med
; 378(4): 354-369, 2018 01 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-29365309
6.
The Current Management of Hepatorenal Syndrome-Acute Kidney Injury in the United States and the Potential of Terlipressin.
Liver Transpl
; 27(8): 1191-1202, 2021 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-33848394
7.
Safety and Efficacy of Segmental Yttrium-90 Radioembolization for Hepatocellular Carcinoma after Transjugular Intrahepatic Portosystemic Shunt Creation.
J Vasc Interv Radiol
; 32(2): 211-219, 2021 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-33349507
8.
Sofosbuvir, Velpatasvir, and Voxilaprevir for Previously Treated HCV Infection.
N Engl J Med
; 376(22): 2134-2146, 2017 06 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-28564569
9.
Reply.
Clin Gastroenterol Hepatol
; 22(2): 436-437, 2024 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-37543100
10.
Efficacy and Pharmacokinetics of Glecaprevir and Pibrentasvir With Concurrent Use of Acid-Reducing Agents in Patients With Chronic HCV Infection.
Clin Gastroenterol Hepatol
; 17(3): 527-535.e6, 2019 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-30012435
11.
Glecaprevir/Pibrentasvir in patients with chronic HCV genotype 3 infection: An integrated phase 2/3 analysis.
J Viral Hepat
; 26(3): 337-349, 2019 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-30421537
12.
Institutional decision to adopt Y90 as primary treatment for hepatocellular carcinoma informed by a 1,000-patient 15-year experience.
Hepatology
; 68(4): 1429-1440, 2018 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-29194711
13.
No impact of resistance-associated substitutions on the efficacy of sofosbuvir, velpatasvir, and voxilaprevir for 12â¯weeks in HCV DAA-experienced patients.
J Hepatol
; 69(6): 1221-1230, 2018 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-30098373
14.
Sofosbuvir and Velpatasvir for HCV in Patients with Decompensated Cirrhosis.
N Engl J Med
; 373(27): 2618-28, 2015 Dec 31.
Artigo
em Inglês
| MEDLINE | ID: mdl-26569658
15.
Patient-Reported Outcomes Following Treatment of Chronic Hepatitis C Virus Infection With Sofosbuvir and Velpatasvir, With or Without Voxilaprevir.
Clin Gastroenterol Hepatol
; 16(4): 567-574.e6, 2018 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-29155352
16.
Glecaprevir and pibrentasvir for 12 weeks for hepatitis C virus genotype 1 infection and prior direct-acting antiviral treatment.
Hepatology
; 66(2): 389-397, 2017 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-28128852
17.
Hepatocellular carcinoma decreases the chance of successful hepatitis C virus therapy with direct-acting antivirals.
J Hepatol
; 66(6): 1173-1181, 2017 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-28161470
18.
Evaluation of proton pump inhibitor use on treatment outcomes with ledipasvir and sofosbuvir in a real-world cohort study.
Hepatology
; 64(6): 1893-1899, 2016 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-27533287
19.
Ledipasvir and Sofosbuvir Plus Ribavirin for Treatment of HCV Infection in Patients With Advanced Liver Disease.
Gastroenterology
; 149(3): 649-59, 2015 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-25985734
20.
To Transplant or Not to Transplant: Understanding and Assessing the Liver-Kidney Allocation Policy.
Liver Transpl
; 27(11): 1527-1528, 2021 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-34273226